Annual Accounts Receivable
$1.21 M
-$4.78 M-79.85%
31 December 2023
Summary:
Nektar Therapeutics annual accounts receivable is currently $1.21 million, with the most recent change of -$4.78 million (-79.85%) on 31 December 2023. During the last 3 years, it has fallen by -$37.68 million (-96.90%). NKTR annual accounts receivable is now -97.44% below its all-time high of $47.15 million, reached on 31 December 2006.NKTR Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$0.00
-$1.20 M-100.00%
30 September 2024
Summary:
Nektar Therapeutics quarterly accounts receivable is currently $0.00, with the most recent change of -$1.20 million (-100.00%) on 30 September 2024. Over the past year, it has dropped by -$2.20 million (-100.00%). NKTR quarterly accounts receivable is now -100.00% below its all-time high of $64.75 million, reached on 31 March 2007.NKTR Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NKTR Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -79.8% | -100.0% |
| 3 y3 years | -96.9% | -100.0% |
| 5 y5 years | -97.2% | -100.0% |
NKTR Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -96.9% | at low | -100.0% | |
| 5 y | 5 years | -97.2% | at low | -100.0% | |
| alltime | all time | -97.4% | at low | -100.0% |
Nektar Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $0.00(-100.0%) |
| June 2024 | - | $1.20 M(-66.9%) |
| Mar 2024 | - | $3.62 M(+200.2%) |
| Dec 2023 | $1.21 M(-79.9%) | $1.21 M(-45.3%) |
| Sept 2023 | - | $2.20 M(+65.1%) |
| June 2023 | - | $1.33 M(-55.4%) |
| Mar 2023 | - | $3.00 M(-49.9%) |
| Dec 2022 | $5.98 M(-73.4%) | $5.98 M(-48.1%) |
| Sept 2022 | - | $11.53 M(+15.3%) |
| June 2022 | - | $10.01 M(-66.9%) |
| Mar 2022 | - | $30.22 M(+34.4%) |
| Dec 2021 | $22.49 M(-42.2%) | $22.49 M(-22.4%) |
| Sept 2021 | - | $28.99 M(+0.4%) |
| June 2021 | - | $28.87 M(-1.0%) |
| Mar 2021 | - | $29.16 M(-25.0%) |
| Dec 2020 | $38.89 M(+5.7%) | $38.89 M(-9.4%) |
| Sept 2020 | - | $42.92 M(-9.1%) |
| June 2020 | - | $47.24 M(+12.4%) |
| Mar 2020 | - | $42.03 M(+14.2%) |
| Dec 2019 | $36.80 M(-14.8%) | $36.80 M(-10.7%) |
| Sept 2019 | - | $41.20 M(+10.5%) |
| June 2019 | - | $37.30 M(-13.0%) |
| Mar 2019 | - | $42.89 M(-0.7%) |
| Dec 2018 | $43.21 M(+761.8%) | $43.21 M(+35.3%) |
| Sept 2018 | - | $31.94 M(-9.6%) |
| June 2018 | - | $35.31 M(+126.3%) |
| Mar 2018 | - | $15.61 M(+211.3%) |
| Dec 2017 | $5.01 M(-68.0%) | $5.01 M(+51.3%) |
| Sept 2017 | - | $3.31 M(-19.4%) |
| June 2017 | - | $4.11 M(+162.9%) |
| Mar 2017 | - | $1.56 M(-90.0%) |
| Dec 2016 | $15.68 M(-21.4%) | $15.68 M(+10.0%) |
| Sept 2016 | - | $14.25 M(-48.7%) |
| June 2016 | - | $27.78 M(-30.0%) |
| Mar 2016 | - | $39.68 M(+98.9%) |
| Dec 2015 | $19.95 M(+453.0%) | $19.95 M(+572.5%) |
| Sept 2015 | - | $2.97 M(-19.4%) |
| June 2015 | - | $3.68 M(+27.6%) |
| Mar 2015 | - | $2.88 M(-20.0%) |
| Dec 2014 | $3.61 M(+61.8%) | $3.61 M(-92.2%) |
| Sept 2014 | - | $46.07 M(+1412.1%) |
| June 2014 | - | $3.05 M(+64.3%) |
| Mar 2014 | - | $1.85 M(-16.8%) |
| Dec 2013 | $2.23 M(-61.6%) | $2.23 M(-51.1%) |
| Sept 2013 | - | $4.56 M(-24.6%) |
| June 2013 | - | $6.04 M(+65.6%) |
| Mar 2013 | - | $3.65 M(-37.2%) |
| Dec 2012 | $5.80 M | $5.80 M(+48.4%) |
| Sept 2012 | - | $3.91 M(-65.6%) |
| June 2012 | - | $11.36 M(+5.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2012 | - | $10.80 M(+118.8%) |
| Dec 2011 | $4.94 M(-80.3%) | $4.94 M(-61.8%) |
| Sept 2011 | - | $12.91 M(+52.6%) |
| June 2011 | - | $8.46 M(+291.7%) |
| Mar 2011 | - | $2.16 M(-91.4%) |
| Dec 2010 | $25.10 M(+422.8%) | $25.10 M(+352.0%) |
| Sept 2010 | - | $5.55 M(-41.2%) |
| June 2010 | - | $9.45 M(+22.5%) |
| Mar 2010 | - | $7.71 M(+60.6%) |
| Dec 2009 | $4.80 M(-57.0%) | $4.80 M(-24.2%) |
| Sept 2009 | - | $6.33 M(+9.2%) |
| Mar 2009 | - | $5.80 M(-48.1%) |
| Dec 2008 | $11.16 M(-48.4%) | $11.16 M(+31.1%) |
| Sept 2008 | - | $8.52 M(-29.4%) |
| June 2008 | - | $12.07 M(-14.1%) |
| Mar 2008 | - | $14.04 M(-35.1%) |
| Dec 2007 | $21.64 M(-54.1%) | $21.64 M(-41.2%) |
| Sept 2007 | - | $36.80 M(-26.1%) |
| June 2007 | - | $49.83 M(-23.0%) |
| Mar 2007 | - | $64.75 M(+37.3%) |
| Dec 2006 | $47.15 M(+474.6%) | $47.15 M(+32.9%) |
| Sept 2006 | - | $35.49 M(-20.5%) |
| June 2006 | - | $44.64 M(+156.1%) |
| Mar 2006 | - | $17.43 M(+112.5%) |
| Dec 2005 | $8.21 M(-36.1%) | $8.21 M(-43.6%) |
| Sept 2005 | - | $14.55 M(+39.3%) |
| June 2005 | - | $10.45 M(+65.0%) |
| Mar 2005 | - | $6.33 M(-50.7%) |
| Dec 2004 | $12.84 M(+108.7%) | $12.84 M(+127.6%) |
| Sept 2004 | - | $5.64 M(-70.2%) |
| June 2004 | - | $18.94 M(+431.7%) |
| Mar 2004 | - | $3.56 M(-42.1%) |
| Dec 2003 | $6.15 M(+40.8%) | $6.15 M(-29.5%) |
| Sept 2003 | - | $8.72 M(-1.4%) |
| June 2003 | - | $8.85 M(+30.6%) |
| Mar 2003 | - | $6.78 M(+55.0%) |
| Dec 2002 | $4.37 M(-2.6%) | $4.37 M(+17.8%) |
| Sept 2002 | - | $3.71 M(-23.5%) |
| June 2002 | - | $4.85 M(+8.3%) |
| Mar 2002 | - | $4.48 M(-0.2%) |
| Dec 2001 | $4.49 M(-38.0%) | $4.49 M(-15.7%) |
| Sept 2001 | - | $5.32 M(-48.8%) |
| June 2001 | - | $10.39 M(+211.7%) |
| Mar 2001 | - | $3.33 M(-53.9%) |
| Dec 2000 | $7.23 M(+312.0%) | $7.23 M(+272.5%) |
| Sept 2000 | - | $1.94 M(-16.3%) |
| June 2000 | - | $2.32 M(+240.3%) |
| Mar 2000 | - | $682.00 K(-61.2%) |
| Dec 1999 | $1.76 M | $1.76 M(+50.5%) |
| Sept 1999 | - | $1.17 M(-91.4%) |
| June 1999 | - | $13.63 M |
FAQ
- What is Nektar Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Nektar Therapeutics?
- What is Nektar Therapeutics annual accounts receivable year-on-year change?
- What is Nektar Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Nektar Therapeutics?
- What is Nektar Therapeutics quarterly accounts receivable year-on-year change?
What is Nektar Therapeutics annual accounts receivable?
The current annual accounts receivable of NKTR is $1.21 M
What is the all time high annual accounts receivable for Nektar Therapeutics?
Nektar Therapeutics all-time high annual accounts receivable is $47.15 M
What is Nektar Therapeutics annual accounts receivable year-on-year change?
Over the past year, NKTR annual accounts receivable has changed by -$4.78 M (-79.85%)
What is Nektar Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of NKTR is $0.00
What is the all time high quarterly accounts receivable for Nektar Therapeutics?
Nektar Therapeutics all-time high quarterly accounts receivable is $64.75 M
What is Nektar Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, NKTR quarterly accounts receivable has changed by -$2.20 M (-100.00%)